August 14, 2000
AMERIPATH, INC. APPOINTS BRUCE C. WALTON AS V.P. OF SALES AND MARKETING

Riviera Beach, FL, August 14, 2000 – AmeriPath, Inc. (Nasdaq: PATH), the largest physician and laboratory company focused on providing anatomic pathology cancer diagnostic and healthcare information services, today announced the appointment of Bruce C. Walton to its Executive Management team as Vice President of Sales and Marketing. He has over 17 years experience in various sales and management positions, most of it as an employee at C.R. Bard, Inc., a surgical device manufacturer. Over the past year, he has restructured, hired, and trained a dynamic sales team, contributing to AmeriPath’s increase in same practice revenue growth from 4% to 15%. Walton is looking to expand the role of marketing, sales, and contracting, bringing AmeriPath toward being the recognized leader in diagnostic information services.

James C. New, the Company’s Chairman and CEO, noted that, “We are pleased that someone with Bruce’s experience is leading AmeriPath’s sales and marketing efforts in providing value to our pathology practices through the growth and differentiation of their services, and to guide us in the direction of becoming a national diagnostic healthcare information provider.”

In his new role, Walton is responsible for directing all activities related to the Company’s Sales, Marketing, and Contracting departments. He received his B.S. degree in Business Administration from Indiana University of Pennsylvania.

Walton lives in Palm Beach Gardens, Florida with his wife and four daughters.

AmeriPath, Inc. is the nation’s largest physician and laboratory company focused on providing anatomic pathology diagnostic and healthcare information services to physicians, hospitals, national clinical laboratories and managed care organizations. The company presently operates in 13 states and employs 301 physicians that provide medical services through outpatient pathology laboratories, hospital inpatient laboratories and outpatient surgery centers.

...............................................................................................................................

This release contains certain forward-looking statements regarding AmeriPath, including its operations and prospects. Past performance is not necessarily indicative of future results. In addition, AmeriPath’s actual results could differ materially from the results anticipated in these forward-looking statements as a result of uncertainties, including risks relating to demand, pricing, government regulation, payments and reimbursements, dependence upon contracts and pathologists, acquisitions, integration of acquired practices, the market for pathology services, competition, technology and other factors identified in AmeriPath’s filings with the Securities and Exchange Commission.